Effect of Arginine on the Aggregation of Protein in Freeze-Dried Formulations Containing Sugars and Polyol: II. BSA Reconstitution and Aggregation

被引:0
作者
Ellen Hackl
Joseph Darkwah
Geoff Smith
Irina Ermolina
机构
[1] De Montfort University,Leicester School of Pharmacy, Faculty of Health and Life Sciences
[2] University of Reading,School of Pharmacy
来源
AAPS PharmSciTech | 2018年 / 19卷
关键词
freeze-drying; protein aggregation; -arginine; mannitol; trehalose;
D O I
暂无
中图分类号
学科分类号
摘要
The current paper continues our study on the ability of l-arginine to prevent/reduce the aggregation of proteins that results from the various stresses during the lyophilisation and/or storage of lyophilized protein-based products. The first part of our study, i.e. formulation development, was devoted to the rational design and optimization of an l-arginine containing lyophilized formulation which can resist the natural tendency of l-arginine to absorb atmosphere moisture. Mannitol and trehalose were chosen among other excipients to be included in the protein-based formulation, as mannitol in a combination with l-arginine has been shown to reduce moisture sorption while trehalose provides a degree of lyoprotection. In the present study, a number of formulations, which comprised bovine serum albumin (BSA) with and without l-arginine, and with five different ratios of trehalose-to-mannitol (from 30:70 to 80:20) were lyophilised and assessed. The internal structures and the moisture sorption/retention of the lyophilized formulations were characterised. To study the effect of l-arginine on BSA solid-phase stability, the lyophilized powder was exposed to accelerated storage conditions (high moisture (75% RH) and temperature (22 or 45 °C)) for up to 24 h. The lyophilized BSA formulations were then reconstituted and solution-state protein aggregation assessed by turbidimetry at 360 nm and fluorescence spectroscopy using the thioflavin T assay. It was demonstrated that l-arginine can be used in protein-based freeze-dried formulations to significantly reduce the aggregation of protein during the manufacturing, storage and subsequent reconstitution. The results also revealed the importance of a sufficient amount of mannitol in the arginine-containing formulations.
引用
收藏
页码:2934 / 2947
页数:13
相关论文
共 194 条
  • [1] Carpenter JF(2002)Rational design of stable lyophilized protein formulations: theory and practice Pharm Biotechnol 13 109-133
  • [2] Chang BS(2010)Stability of protein pharmaceuticals: an update Pharm Res 27 544-575
  • [3] Garzon-Rodriguez W(2014)Stabilization of therapeutic proteins in aqueous solutions and freeze-dried solids: an overview Methods Mol Biol 1129 435-441
  • [4] Randolph TW(2000)Lyophilization and development of solid protein pharmaceuticals Int J Pharm 203 1-60
  • [5] Manning MC(2012)Development of stable lyophilized protein drug products Curr Pharm Biotechnol 13 471-496
  • [6] Chou DK(2015)Freeze-drying of live virus vaccines: a review Vaccine 33 5507-5519
  • [7] Murphy BM(2017)Mini review: recombinant production of tailored bio-pharmaceuticals in different Bacillus strains and future perspectives Eur J Pharm Biopharm 126 27-39
  • [8] Payne RW(2001)Factors affecting short-term and long-term stabilities of proteins Adv Drug Deliv Rev 46 307-326
  • [9] Katayama DS(2014)Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies Nat Rev Drug Discov 13 655-672
  • [10] Izutsu K(2006)Protein aggregation and bioprocessing AAPS J 8 E572-E579